Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation

Nutritional supplements manufacturer Pharmavite has filed an antitrust suit against Bausch & Lomb and GlaxoSmithKline (GSK), claiming that they are filing sham patent litigation related to its “PreserVision” products

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

GSK to buy Sierra Oncology for $1.9bn

14 April 2022 GlaxoSmithKline has agreed to acquire California-based biopharma company Sierra Oncology for $1.9 billion, in a move that bolsters the UK company’s cancer business.

Americas

Bausch & Lomb looks to protect patents in eyedrop lawsuit

26 October 2021 Bausch & Lomb has accused a Nashville-based ophthalmic company of infringing two patents covering its eye-brightening drops, Lumify.

Big Pharma

Bausch settles $300m antitrust case over diabetes drug price hikes

13 September 2021 Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation

More on this story

Editor's picks

Editor's picks

More features